Y Intercept Hong Kong Ltd Buys 30,526 Shares of Guardant Health, Inc. $GH

Y Intercept Hong Kong Ltd lifted its stake in Guardant Health, Inc. (NASDAQ:GH) by 66.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 76,295 shares of the company’s stock after purchasing an additional 30,526 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Guardant Health were worth $4,767,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also added to or reduced their stakes in GH. IFP Advisors Inc boosted its position in shares of Guardant Health by 120.1% during the second quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after buying an additional 334 shares during the last quarter. Signaturefd LLC grew its position in Guardant Health by 50.5% during the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after buying an additional 213 shares during the period. Allworth Financial LP boosted its stake in shares of Guardant Health by 358.4% during the 2nd quarter. Allworth Financial LP now owns 706 shares of the company’s stock worth $37,000 after acquiring an additional 552 shares during the last quarter. Sound Income Strategies LLC purchased a new stake in shares of Guardant Health in the 3rd quarter worth $38,000. Finally, FNY Investment Advisers LLC bought a new position in Guardant Health in the 2nd quarter worth $62,000. 92.60% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on GH shares. JPMorgan Chase & Co. upped their price target on Guardant Health from $90.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Evercore ISI set a $105.00 price objective on Guardant Health and gave the company an “in-line” rating in a research note on Monday, January 5th. Leerink Partners increased their target price on shares of Guardant Health from $115.00 to $155.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Barclays lifted their price target on shares of Guardant Health from $85.00 to $120.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Finally, Wells Fargo & Company upped their price target on shares of Guardant Health from $93.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Twenty-one investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $102.81.

Insider Activity

In other news, insider Terilyn J. Monroe sold 55,167 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $105.97, for a total transaction of $5,846,046.99. Following the sale, the insider directly owned 20,920 shares of the company’s stock, valued at $2,216,892.40. This represents a 72.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael Brian Bell sold 80,362 shares of the stock in a transaction on Friday, December 5th. The shares were sold at an average price of $103.14, for a total transaction of $8,288,536.68. Following the transaction, the chief financial officer owned 28,052 shares of the company’s stock, valued at $2,893,283.28. This trade represents a 74.13% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 445,123 shares of company stock valued at $46,600,702. 6.10% of the stock is owned by corporate insiders.

Guardant Health Price Performance

Guardant Health stock opened at $114.75 on Monday. The stock has a market cap of $14.46 billion, a P/E ratio of -35.75 and a beta of 1.58. Guardant Health, Inc. has a 1 year low of $34.88 and a 1 year high of $120.74. The firm’s 50 day moving average price is $105.24 and its 200-day moving average price is $77.82.

Guardant Health (NASDAQ:GH) last issued its earnings results on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.09. Guardant Health’s quarterly revenue was up 38.5% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.88) EPS. As a group, equities analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current year.

About Guardant Health

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.